2-methyl-3-(3-methoxy-phenyl)propan-1-ol | 16123-41-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-methyl-3-(3-methoxy-phenyl)propan-1-ol
• 英文别名: 3-(3-methoxyphenyl)-2-methylpropan-1-ol；3-(m-Methoxyphenyl)-2-methyl-1-propanol；dl-3-(m-methoxyphenyl)-2-methyl-1-propanol
• CAS: 16123-41-4
• 化学式: C₁₁H₁₆O₂
• 分子量: 180.247
• InChiKey: ODGYOAXTUWWPEZ-UHFFFAOYSA-N

物化性质

• 沸点：
  292.2±15.0 °C(Predicted)
• 密度：
  1.017±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-methyl-3-(3-methoxy-phenyl)propan-1-ol 在 Py*HClCrO₃ 作用下， 以 二氯甲烷 为溶剂， 生成 3-methoxy-α-methyl-benzenepropanal
  参考文献：
  名称：

  Groen,M.B.; Zeelen,F.J., Recueil des Travaux Chimiques des Pays-Bas, 1978, vol. 97, # 11, p. 301 - 304

  摘要：

  DOI：
• 作为产物：
  描述：

  3-(3-methoxyphenyl)-2-methylacrylaldehyde 在 chlorine[2-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxypyridine](pentamethylcyclopentadienyl)iridium(III) chloride 、 sodium formate 作用下， 以 水 为溶剂， 反应 0.5h， 以95%的产率得到2-methyl-3-(3-methoxy-phenyl)propan-1-ol
  参考文献：
  名称：

  高度依赖pH的水中α，β-不饱和醛的化学选择性转移加氢

  摘要：

  在水中实现了pH依赖的选择性Ir催化的α，β-不饱和醛的加氢反应。在低pH下使用HCOOH作为氢化物供体，仅获得不饱和醇产物，而在高pH下，优先使用HCOONa作为氢化物供体形成饱和醇产物。可以耐受包括α，β-不饱和醛的芳基上的富电子以及贫电子取代基在内的各种官能团，从而以高收率提供具有高收率的相应产物。还观察到具有脂族取代基的α，β-不饱和醛的高选择性和产率。我们的机理研究表明，pH值对化学选择性至关重要。

  DOI：

  10.1021/acs.organomet.9b00353

文献信息

• Nickel-Catalyzed Asymmetric Kumada Cross-Coupling of Symmetric Cyclic Sulfates
  作者：Meredith S. Eno、Alexander Lu、James P. Morken

  DOI：10.1021/jacs.6b03384

  日期：2016.6.29

  Nickel-catalyzed enantioselective cross-couplings between symmetric cyclic sulfates and aromatic Grignard reagents are described. These reactions are effective with a broad range of substituted cyclic sulfates and deliver products with asymmetric tertiary carbon centers. Mechanistic experiments point to a stereoinvertive SN2-like oxidative addition of a nickel complex to the electrophilic substrate

  描述了对称环状硫酸盐和芳香格氏试剂之间的镍催化的对映选择性交叉偶联。这些反应对广泛的取代环硫酸盐有效，并提供具有不对称叔碳中心的产物。机理实验表明，镍络合物在亲电子底物上发生了立体反转的 SN2 样氧化加成反应。
• Highly enantioselective hydrogenation of 2-substituted-2-alkenols catalysed by a ChenPhos–Rh complex
  作者：Quanjun Wang、Xueying Liu、Xian Liu、Bin Li、Huifang Nie、Shengyong Zhang、Weiping Chen

  DOI：10.1039/c3cc47727d

  日期：——

  Highly enantioselective hydrogenation of a variety of 2-substituted-2-alkenols has been achieved using a ChenPhos–Rh complex as catalyst, giving ≥99% ee for most substrates. Optically active antifungal agent amorolfine was first synthesised using hydrogenation as the key step.

  已经成功地使用ChenPhos–Rh复合物作为催化剂，对多种2-取代-2-烯醇进行了高度的对映选择性氢化，为大多数底物提供了≥99%的对映体过量（ee）。光学活性抗真菌剂阿莫洛芬首次通过氢化作为关键步骤合成。
• Cyclization substrates and 7.alpha.-substituted 19-norsteroid derivatives
  申请人：Akzona Inc.

  公开号：US04177197A1

  公开（公告）日：1979-12-04

  Novel cyclization substrates are disclosed of the formula ##STR1## wherein: (a) R.sub.1 is H or alkyl of one to four carbon atoms; (b) R.sub.2 is H or alkyl of one to four carbon atoms, with the proviso that R.sub.1 is H when R.sub.2 is alkyl, and with the proviso that R.sub.2 is H when R.sub.1 is alkyl; (c) R.sub.3 is a leaving group selected from the group consisting of hydroxy, alkoxy of one to four carbons, alkoxyalkoxy of two to four carbons, acyloxy of one to about seven carbons, and trialkylsilyloxy of less than fifteen carbons; (d) R.sub.4 is hydrocarbyl of one to four carbon atoms, a hydrocarbyl of one to two carbon atoms substituted by halogen or alkoxy of one to two carbons, or alkoxy of one to four carbon atoms; and (e) R.sub.5 and R.sub.5 ' each are H, OH, alkyl, trialkylsilyloxy, or an esterified or etherified hydroxy-group of about one to ten carbon atoms. A method is disclosed for the cyclization of the compounds of formula III leading to novel and biologically active compounds of the following formulae: ##STR2## having R.sub.1 through R.sub.5 ' as defined above, with R.sub.6 being alkyl of from one to about four carbon atoms, among which are intermediates for preparing well-known biologically active 7.alpha.-substituted steroids, such as 7.alpha.-methyl-oestrone; 7.alpha.-methoxy-oestradiol and the like.

  揭示了一种新颖的环化底物，其化学式为##STR1##其中：(a) R.sub.1为H或含有一至四个碳原子的烷基；(b) R.sub.2为H或含有一至四个碳原子的烷基，条件是当R.sub.2为烷基时，R.sub.1为H，且当R.sub.1为烷基时，R.sub.2为H；(c) R.sub.3为从羟基、含有一至四个碳原子的烷氧基、含有两至四个碳原子的烷氧基、含有一至约七个碳原子的酰氧基、少于十五个碳原子的三烷基硅氧基中选择的离去基团；(d) R.sub.4为含有一至四个碳原子的烃基，或者被卤素或含有一至两个碳原子的烷氧基取代的含有一至两个碳原子的烃基，或者含有一至四个碳原子的烷氧基；(e) R.sub.5和R.sub.5'分别为H、OH、烷基、三烷基硅氧基，或者约一至十个碳原子的酯化或醚化羟基。揭示了一种用于将化合物III的环化的方法，导致以下式的新型生物活性化合物：##STR2##其中R.sub.1至R.sub.5'如上定义，R.sub.6为含有一至约四个碳原子的烷基，其中包括制备已知生物活性7α-取代类固醇的中间体，例如7α-甲基雌二醇；7α-甲氧基雌二醇等。
• Benzolactam compounds as protein kinase inhibitors
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US10457669B2

  公开（公告）日：2019-10-29

  The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof. The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.

  本发明提供了一种式 (0) 的化合物： 或其药学上可接受的盐、N-氧化物或同系物；其中 n 是 1 或 2 X 是 CH 或 N Y 选自 CH 和 C-F Z 选自 C-Rz 和 N； R1 选自 -(Alk1)t-Cyc1；其中 t 为 0 或 1； 任选取代的 C1-6 无环烃基团 R2 选自氢、卤素和任选被一个或多个氟原子取代的 C1-3 烃基； R3 是氢或基团 L1-R7； R4 选自氢、甲氧基和任选被取代的 C1-3 烷基；以及 R4a 选自氢和 C1-3 烷基； 其中 Rz、Alk1、Cyc1、L1 和 R7 在本文中定义； 只要该化合物不是 6-苄基-3-2-[(2-甲基嘧啶-4-基)氨基]吡啶-4-基}-7,8-二氢-1,6-萘啶-5(6H)-酮和 3-2-[(2-甲基嘧啶-4-基)氨基]吡啶-4-基}-7,8-二氢-1,6-萘啶-5(6H)-酮及其盐和它们的同系物。 这些化合物是 ERK1/2 激酶的抑制剂，可用于治疗 ERK1/2 介导的疾病。因此，这些化合物可用于治疗，特别是治疗癌症。
• BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20190047990A1

  公开（公告）日：2019-02-14

  The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—R z and N; R 1 is selected from: -(Alk 1 ) t -Cyc 1 ; wherein t is 0 or 1; Optionally substituted C 1-6 acyclic hydrocarbon groups R 2 is selected from hydrogen; halogen; and C 1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R 3 is hydrogen or a group L 1 -R 7 ; R 4 is selected from hydrogen; methoxy; and optionally substituted C 1-3 alkyl; and R 4a is selected from hydrogen and a C 1-3 alkyl group; wherein R z , Alk 1 , Cyc 1 , L 1 and R 7 are defined herein; provided that the compound is other than 6-benzyl-3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof. The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.